North American Vaccine Inc. reported yesterday a net loss of $11 million, or 34 cents a share, for its second quarter, compared with a net loss of $11.2 million, or 36 cents a share, for the same quarter last year.

The Beltsville company, which is developing vaccines for infectious diseases, said revenue for the three months that ended June 30 was $1.2 million, up from $1.1 million in the year-ago period.

The company said revenue for the three-month periods in 1998 and 1997 came primarily from research and licensing agreements and product sales of the company's whooping cough vaccine in Europe.

Pub Date: 8/15/98